Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
4(36%)
Results Posted
14%(1 trials)

Phase Distribution

Ph phase_3
2
18%
Ph phase_2
1
9%
Ph phase_4
1
9%
Ph phase_1
7
64%

Phase Distribution

7

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
7(63.6%)
Phase 2Efficacy & side effects
1(9.1%)
Phase 3Large-scale testing
2(18.2%)
Phase 4Post-market surveillance
1(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

11

all time

Status Distribution
Active(4)
Completed(7)

Detailed Status

Completed7
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
11
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (63.6%)
Phase 21 (9.1%)
Phase 32 (18.2%)
Phase 41 (9.1%)

Trials by Status

recruiting436%
completed764%

Recent Activity

4 active trials
Showing 5 of 11
recruitingphase_3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624
recruitingphase_3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

NCT06136650
recruitingphase_1

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

NCT07548606
completedphase_1

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

NCT06104449
recruitingphase_1

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

NCT06353386
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT06136624Phase 3

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

Recruiting
NCT06136650Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Recruiting
NCT07548606Phase 1

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

Recruiting
NCT06104449Phase 1

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Completed
NCT06353386Phase 1

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Recruiting
NCT06860243Phase 1

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

Completed
NCT06814132Phase 1

A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)

Completed
NCT06633419Phase 1

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

Completed
NCT06554639Phase 1

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

Completed
NCT04494789Phase 2

Fludrocortisone Dose Response Relationship in Septic Shock - FluDReSS

Completed
NCT00118482Phase 4

Clinical Trial for the Prevention of Vasovagal Syncope

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11